{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:41:58Z","timestamp":1791420118119,"version":"4.3.3"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The clinical potency of anti-programmed death-ligand 1 (PD-L1) therapy in metastatic triple-negative breast cancer (TNBC) is modest primarily because of the intrinsic low immunogenicity and an immunosuppressive tumor microenvironment (TME). Photodynamic therapy (PDT), an inducer of immunogenic cell death (ICD), has the potential to enhance antitumor immune response and improve PD-L1 blockade efficacy. DTP, a novel photosensitizer developed previously, has demonstrated potent ROS-dependent photocytotoxicity, yet its immunomodulatory effects remain unexplored. This study investigated the induction of ICD and dendritic cell (DC) maturation following DTP-PDT <jats:italic>in vivo<\/jats:italic> and <jats:italic>in vitro<\/jats:italic>. A bilateral TNBC model was developed to assess the efficacy of DTP-PDT combined with \u03b1-PD-L1 therapy on untreated distant tumors and to explore its potential immunological mechanisms. The results showed that DTP-PDT effectively induced ICD, demonstrated by calreticulin membrane exposure, high mobility group box 1 protein release, and increased secretion of interferon-\u03b3 and tumor necrosis factor-\u03b1, resulting in DC maturation. The combination of DTP-PDT and \u03b1-PD-L1 significantly inhibited distant tumor growth. This effect was associated with increased CD8<jats:sup>+<\/jats:sup> and CD4<jats:sup>+<\/jats:sup> T cells infiltration, and reduced numbers of regulatory T cells, in the distant tumor and spleen. In conclusion, DTP-PDT enhanced TNBC sensitivity to \u03b1-PD-L1 by inducing ICD, and its combination with\u03b1-PD-L1 could remodel the immunosuppressive TME and enhance systemic immunity, resulting in a therapeutic effect against distant metastasis. This study provides experimental validation for a combined strategy of DTP-PDT and \u03b1-PD-L1, proposing a potential therapeutic approach for metastatic TNBC.<\/jats:p>","DOI":"10.3389\/fphar.2025.1651165","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T05:24:47Z","timestamp":1752729887000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["An immunomodulatory photosensitizer-mediated photodynamic therapy synergizes with PD-L1 blockade against metastatic triple-negative breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuetong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s13577-015-0127-1","article-title":"Identification of a highly immunogenic mouse breast cancer sub cell line, 4T1-S","volume":"29","author":"Abe","year":"2016","journal-title":"Hum. Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3322\/caac.20114","article-title":"Photodynamic therapy of cancer: an update","volume":"61","author":"Agostinis","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"112796","DOI":"10.1016\/j.jphotobiol.2023.112796","article-title":"Unleashing the power of porphyrin photosensitizers: illuminating breakthroughs in photodynamic therapy","volume":"248","author":"Akbar","year":"2023","journal-title":"J. Photochem. Photobiol. B Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"104058","DOI":"10.1016\/j.pdpdt.2024.104058","article-title":"Tools of clinical photodynamic therapy (PDT): a mini compendium","volume":"46","author":"Allison","year":"2024","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e001926","DOI":"10.1136\/jitc-2020-001926","article-title":"Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future","volume":"9","author":"Alzeibak","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1084\/jem.192.4.565","article-title":"High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes","volume":"192","author":"Andersson","year":"2000","journal-title":"J. Exp. Med."},{"key":"B7","first-page":"187","article-title":"Chapter 5 - design of porphyrin-based photosensitizers for photodynamic therapy","volume-title":"Advances in inorganic chemistry","author":"Arnaut","year":"2011"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.jaad.2021.02.048","article-title":"Visible light. Part I: properties and cutaneous effects of visible light","volume":"84","author":"Austin","year":"2021","journal-title":"J. Am. Acad. Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1111\/php.13865","article-title":"A single photodynamic priming protocol augments delivery of \u237a-PD-L1 mAbs and induces immunogenic cell death in head and neck tumors","volume":"100","author":"Bhandari","year":"2024","journal-title":"Photochem Photobiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(04)01529-3","article-title":"The present and future role of photodynamic therapy in cancer treatment","volume":"5","author":"Brown","year":"2004","journal-title":"Lancet Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jphotobiol.2015.08.020","article-title":"Effects of a novel porphyrin-based photosensitizer on sensitive and multidrug-resistant human gastric cancer cell lines","volume":"151","author":"Chen","year":"2015","journal-title":"J. Photochem. Photobiol. B Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"911","DOI":"10.32604\/or.2023.042384","article-title":"Antitumor effects of a novel photosensitizer-mediated photodynamic therapy and its influence on the cell transcriptome","volume":"32","author":"Chen","year":"2024","journal-title":"Oncol. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3892\/ol.2015.3953","article-title":"Photodynamic therapy with a novel porphyrin-based photosensitizer against human gastric cancer","volume":"11","author":"Chen","year":"2016","journal-title":"Oncol. Lett."},{"key":"B14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jphotobiol.2017.04.037","article-title":"Effects of a novel photoactivated photosensitizer on MDR1 over-expressing human breast cancer cells","volume":"171","author":"Chen","year":"2017","journal-title":"J. Photochem. Photobiol. B Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/s0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"vi13","DOI":"10.1093\/annonc\/mds188","article-title":"Understanding the biology of triple-negative breast cancer","volume":"23","author":"Criscitiello","year":"2012","journal-title":"Ann. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/jnci\/82.1.34","article-title":"Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages","volume":"82","author":"Evans","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"B18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S1471-4906(01)02005-1","article-title":"IFN-\u03b3 production by antigen-presenting cells: mechanisms emerge","volume":"22","author":"Frucht","year":"2001","journal-title":"Trends Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.Cd-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov."},{"key":"B21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12672-022-00482-5","article-title":"The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancer","volume":"13","author":"Goda","year":"2022","journal-title":"Discov. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jconrel.2024.02.030","article-title":"Enhancing photodynamic immunotherapy by reprograming the immunosuppressive tumor microenvironment with hypoxia relief","volume":"368","author":"He","year":"2024","journal-title":"J. Control Release"},{"key":"B23","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.it.2016.08.012","article-title":"Induced regulatory T cells: their development, stability, and applications","volume":"37","author":"Kanamori","year":"2016","journal-title":"Trends Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"B25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/ijms22020523","article-title":"Role of CD4+ T cells in the control of viral infections: recent advances and open questions","volume":"22","author":"Kervevan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/cac2.12539","article-title":"Immunologic tumor microenvironment modulators for turning cold tumors hot","volume":"44","author":"Khosravi","year":"2024","journal-title":"Cancer Commun. (Lond)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"11774","DOI":"10.1073\/pnas.1410626111","article-title":"Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells","volume":"111","author":"Kim","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B28","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e071674","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"Bmj"},{"key":"B30","doi-asserted-by":"publisher","first-page":"101387","DOI":"10.1016\/j.mtbio.2024.101387","article-title":"AIEgen-self-assembled nanoparticles with anti-PD-L1 antibody functionalization realize enhanced synergistic photodynamic therapy and immunotherapy against malignant melanoma","volume":"30","author":"Li","year":"2025","journal-title":"Mater Today Bio"},{"key":"B31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"","journal-title":"J. Hematol. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e2201734","DOI":"10.1002\/advs.202201734","article-title":"Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency","volume":"9","author":"Li","year":"","journal-title":"Adv. Sci. (Weinh)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10549-011-1647-3","article-title":"CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes","volume":"130","author":"Liu","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"B34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","article-title":"Advances in immunotherapy for triple-negative breast cancer","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"11667","DOI":"10.1038\/s41598-023-38862-8","article-title":"Photodynamic therapy changes tumour immunogenicity and promotes immune-checkpoint blockade response, particularly when combined with micromechanical priming","volume":"13","author":"Lobo","year":"2023","journal-title":"Sci. Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1158\/1535-7163.Mct-23-0733","article-title":"Combination of bremachlorin PDT and immune checkpoint inhibitor Anti-PD-1 shows response in murine immunological T-cell-High and T-cell-Low PDAC models","volume":"24","author":"McMorrow","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","article-title":"Enhancing anti-tumour efficacy with immunotherapy combinations","volume":"397","author":"Meric-Bernstam","year":"2021","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"13454","DOI":"10.1021\/acs.chemrev.1c00381","article-title":"Recent strategies to develop innovative photosensitizers for enhanced photodynamic therapy","volume":"121","author":"Pham","year":"2021","journal-title":"Chem. Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cytogfr.2007.01.015","article-title":"Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape","volume":"18","author":"Salazar-Onfray","year":"2007","journal-title":"Cytokine Growth Factor Rev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.tcb.2020.06.003","article-title":"The roles of CD8+ T cell subsets in antitumor immunity","volume":"30","author":"St. Paul","year":"2020","journal-title":"Trends Cell Biol."},{"key":"B42","first-page":"27","article-title":"Triple-negative breast cancer therapy: recent advances, challenges, and future perspective","volume-title":"Breast cancer treatment: an interdisciplinary approach","author":"Subhan","year":"2024"},{"key":"B43","doi-asserted-by":"publisher","first-page":"213410","DOI":"10.1016\/j.ccr.2020.213410","article-title":"Recent advances of multi-dimensional porphyrin-based functional materials in photodynamic therapy","volume":"420","author":"Tian","year":"2020","journal-title":"Coord. Chem. Rev."},{"key":"B44","doi-asserted-by":"publisher","first-page":"155442","DOI":"10.1016\/j.cyto.2021.155442","article-title":"The role of cytokines in the evolution of cancer: IFN-\u03b3 paradigm","volume":"151","author":"Todorovi\u0107-Rakovi\u0107","year":"2022","journal-title":"Cytokine"},{"key":"B45","doi-asserted-by":"publisher","first-page":"29368","DOI":"10.1039\/d4ra05585c","article-title":"Porphyrin photosensitizer molecules as effective medicine candidates for photodynamic therapy: electronic structure information aided design","volume":"14","author":"Yin","year":"2024","journal-title":"RSC Adv."},{"key":"B46","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s10120-023-01409-x","article-title":"Photodynamic therapy improves the outcome of immune checkpoint inhibitors via remodelling anti-tumour immunity in patients with gastric cancer","volume":"26","author":"Yu","year":"2023","journal-title":"Gastric Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.7150\/thno.72465","article-title":"How to improve photodynamic therapy-induced antitumor immunity for cancer treatment?","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"key":"B48","doi-asserted-by":"publisher","first-page":"35927","DOI":"10.1021\/acsami.3c05825","article-title":"Porphyrin cholesterol conjugates for enhanced photodynamic immunotherapy toward lung cancer","volume":"15","author":"Zhao","year":"2023","journal-title":"ACS Appl. Mater Interfaces"},{"key":"B49","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1111\/jcmm.14356","article-title":"Immunogenic cell death in cancer therapy: present and emerging inducers","volume":"23","author":"Zhou","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","article-title":"Recent advances in targeted strategies for triple-negative breast cancer","volume":"16","author":"Zhu","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J. Hematol. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1651165\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T05:24:48Z","timestamp":1752729888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1651165\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":51,"alternative-id":["10.3389\/fphar.2025.1651165"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1651165","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"article-number":"1651165"}}